Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1172

Sort by

Sort Order Select

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Protease activity in single-chain prekallikrein

Ivan Ivanov, Ingrid M. Verhamme, Mao-fu Sun, Bassem Mohammed, Qiufang Cheng, Anton Matafonov, S. Kent Dickeson, Kusumam Joseph, Allen P. Kaplan, David Gailani

Blood (2020) 135 (8): 558–567.

https://doi.org/10.1182/blood.2019002224

Published: 2020

Includes: Supplemental data

Journal Articles

Heterozygous Mutations of Clpb As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia

Julia T Warren, MD PhD, Peeradol Wattanasirakul, David H Spencer, MD, Adam Locke, PhD, Vahagn Makaryan, MD, Audrey Anna Bolyard, RN, BS, Karl Welte, Julia Skokowa, MD PhD, David C. Dale, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 433.

https://doi.org/10.1182/blood-2019-129635

Published: 2019

Journal Articles

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

Vahagn Makaryan, MD, Isabella N. Archibald, Merideth L. Kelley, MS, Breanna Fletcher, BSc, David C. Dale, MD

Blood (2019) 134 (Supplement_1): 435.

https://doi.org/10.1182/blood-2019-124988

Published: 2019

Journal Articles

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

Catherine Rondelli, Aiden Danoff, Hector Bergonia, Samantha Gillis, Julia Free, John D. Phillips, PhD, Yvette Y Yien, PhD

Blood (2019) 134 (Supplement_1): 427.

https://doi.org/10.1182/blood-2019-132039

Published: 2019

Journal Articles

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

Vijay Kumar Reddy Kondreddy, MSc,PhD, Usha R. Pendurthi, PhD, Xiao Xu, John H. Griffin, PhD, L. Vijaya Mohan Rao, PhD

Blood (2019) 134 (Supplement_1): 481.

https://doi.org/10.1182/blood-2019-124976

Published: 2019

Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1839.

https://doi.org/10.1182/blood-2019-124828

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Lorena Fontan, PhD, John Hatcher, PhD, David Scott, Qi Qiao, Ilkay Us, Guangyan Du, Matthew Durant, Jimmy Wilson, Hao Wu, PhD, Nathanael Gray, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2073.

https://doi.org/10.1182/blood-2019-130666

Published: 2019

Journal Articles

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Kavitha Godugu, PhD, Shymaa Mousa, Noureldien Hassan Elsayed Darwish, MDPhDBS, Shaker A Mousa, PhD BPharm, MBA, MSc

Blood (2019) 134 (Supplement_1): 3670.

https://doi.org/10.1182/blood-2019-130992

Published: 2019

Journal Articles

Modulation of Thrombin-Induced Platelet Activation By Defibrotide

Kristin N. Maher, MD PhD, Xu Han, BS, MS, Keith B. Neeves, PhD, Marvin T. Nieman, PhD, Jorge Di Paola, MD

Blood (2019) 134 (Supplement_1): 3614.

https://doi.org/10.1182/blood-2019-125945

Published: 2019

Journal Articles

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Michael Wayne Henderson, MSc, Erica Sparkenbaugh, PhD BS, Denis Noubouossie, MD PhD, Reiner Mailer, Thomas Renne, MD PhD, Keith R McCrae, MD, Nigel S. Key, MBChB, FRCP, Rafal Pawlinski, PhD

Blood (2019) 134 (Supplement_1): 3621.

https://doi.org/10.1182/blood-2019-127206

Published: 2019

Journal Articles

Genetic Absence of Integrin alpha2b Improves Survival of Tissue Factor Pathway Inhibitor Null Mice but Results in Hydrocephalus Formation

Michelle Castillo, BS, Emily Ott, BS, Robert Wujek, BS, Liu Qiuli, MD, Kathleen Schmainda, PhD, Susan Cohen, MD, Rashmi Sood, PhD

Blood (2019) 134 (Supplement_1): 3626.

https://doi.org/10.1182/blood-2019-131811

Published: 2019

Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD

Blood (2019) 134 (Supplement_1): 3487.

https://doi.org/10.1182/blood-2019-124832

Published: 2019

Journal Articles

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Xuan Guo, PhD, Srinivas Somanchi, PhD, Rohit Mathur, PhD, Shuyang He, PhD, Qian Ye, PhD, Andrea Difiglia, BS, Salvatore Rotondo, MS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 1576.

https://doi.org/10.1182/blood-2019-127009

Published: 2019

Journal Articles

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

María-Victoria Mateos, MD PhD, Albert Oriol, MD, Alessandra Larocca, Paula Rodriguez Otero, Joan Bladé, MD, Michele Cavo, Hani Hassoun, MD, Xavier Leleu, MD PhD, Adrián Alegre Amor, MD, Christopher Maisel, MD, Agne Paner, MD, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Sara Thuresson, MSc, Hanan Zubair, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1883.

https://doi.org/10.1182/blood-2019-124825

Published: 2019

Journal Articles

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Paul G. Richardson, MD, Swethajit Biswas, Beata Holkova, Nicola Jackson, Thelma Netherway, Weichao Bao, Geraldine Ferron-Brady, Anne Yeakey, Chris Shelton, Rocio Montes De Oca, PhD, Chris Ahlers, Sonia Franco, Marc Ballas, Elaine Paul, Katarina Luptakova, Ira Gupta, Joanna Opalinska

Blood (2019) 134 (Supplement_1): 1857.

https://doi.org/10.1182/blood-2019-129879

Published: 2019

Journal Articles

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Trevor Newhook, MS, Linda Ho, Matthew Mei, MD

Blood (2019) 134 (Supplement_1): 2852.

https://doi.org/10.1182/blood-2019-122968

Published: 2019

Journal Articles

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

Binod Dhakal, MBBS, Muhammad Umair Mushtaq, MD, Ashley Cunningham, MD, Athanasios Papadas, MD, Adam Pagenkopf, BS, Joshua Wiesner, Catherine Leith, MBBChir, Peiman Hematti, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD, Fotis Asimakopoulos, PhDMBBChir,

Blood (2019) 134 (Supplement_1): 3088.

https://doi.org/10.1182/blood-2019-127565

Published: 2019

Journal Articles

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Ken Flanagan, PhD, Muntasir M Majumder, MSc, BPharm, Romika Kumari, PhD, Juho Miettinen, PhD, Ana Slipicevic, PhD, Sarah A. Holstein, MD PhD, Michelle L. Varney, MS, Minna Suvela, MSC, Fredrik Lehmann, PhD, Nina N. Nupponen, PhD, Caroline A Heckman, PhD

Blood (2019) 134 (Supplement_1): 3100.

https://doi.org/10.1182/blood-2019-125952

Published: 2019

NARROW

The different flavors and splices of MCL

Protease activity in single-chain prekallikrein

Heterozygous Mutations of Clpb As a Newly Identified and Frequent Cause of Severe Congenital Neutropenia

CRISPR/Cas9 Mediated ELANE Knock-out Restores Survival and Granulocytic Differentiation of HL60 Cells Expressing Mutant Neutrophil Elastase: Is Neutrophil Elastase a Dispensible Granulocyte Protease?

Regulation of Erythroid Heme Synthesis By the Mitochondrial Clpx Unfoldase

Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas

Effect of Sulfated NON-Anticoagulant Low Molecular Weight Heparin in Cancer and NON-Cancer Associated Thrombosis

Modulation of Thrombin-Induced Platelet Activation By Defibrotide

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Genetic Absence of Integrin alpha2b Improves Survival of Tissue Factor Pathway Inhibitor Null Mice but Results in Hydrocephalus Formation

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Engineering High Affinity and Cleavage Resistant CD16 to Augment ADCC of Placental Hematopoietic Stem Cells-Derived Natural Killer Cells

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above

Versican (VCAN) Proteolysis Predicts Survival in Multiple Myeloma (MM) after High Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT/AHCT)

In Vitro and in Vivo Activity of Melflufen in Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only